IL2 and neoplasm: Indeed, recent case study of the patient with inoperable NSCLC (CT4, cN3, cM0, stage IIIb) treated with autologous ex vivo activated (TKD/IL-2) NK cells with anti-PD-1 antibody as a second-line therapy demonstrated a long-term tumor control [141].